[ A21-159] Ponesimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Last updated 01.03.2022
Project no.:
A21-159
Commission:
Commission awarded on 02.12.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Adult patients with relapsing multiple sclerosis (RMS) with active disease who have not yet received disease-modifying therapy or adult patients with non-highly active disease pretreated with disease-modifying therapy
- Patients with Expanded Disability Status Scale (EDSS) ≤ 3.5: hint of considerable added benefit
- Patients with EDSS > 3.5: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-83 | Ponesimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V | Commission completed |